JUNS (Jupiter Neurosciences) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


JUNS Jupiter Neurosciences Inc JUNS
4 GF Score
Price $0.21
! 6 Warning Signs
View Full Analysis

What is Jupiter Neurosciences ROE % Adjusted to Book Value?

Jupiter Neurosciences JUNS -0.57% 4 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review.

Jupiter Neurosciences's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Jupiter Neurosciences's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Jupiter Neurosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Jupiter Neurosciences ROE % Adjusted to Book Value Related Terms

Jupiter Neurosciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Jupiter Neurosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jupiter Neurosciences ROE % Adjusted to Book Value Chart

Jupiter Neurosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Jupiter Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.77 -15.24 -1.49 0.00 0.00

JUNS vs ZEOX, LEXX, GDTC: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Jupiter Neurosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jupiter Neurosciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Jupiter Neurosciences's ROE % Adjusted to Book Value falls into.


JUNS
4GF Score
Jupiter Neurosciences Inc JUNS
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jupiter Neurosciences ROE % Adjusted to Book Value Calculation

Jupiter Neurosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-738.89% / N/A
=N/A

Jupiter Neurosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Jupiter Neurosciences (JUNS) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Jupiter Neurosciences and its competitors.
Is Jupiter Neurosciences' ROE % Adjusted to Book Value too high?
Jupiter Neurosciences' current ROE % Adjusted to Book Value is 0.00%. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' ROE % Adjusted to Book Value compare to ZEOX and LEXX?
Jupiter Neurosciences' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score

Get the complete analysis for JUNS

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price